Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. MDxHealth SA
  6. News
  7. Summary
    MDXH   BE0003844611

MDXHEALTH SA

(MDXH)
  Report
Real-time Euronext Bruxelles  -  06:53 2022-11-28 am EST
0.6900 EUR   +0.29%
11/04European ADRs Move Higher in Friday Trading
MT
10/27MDxHealth Reports Q3-2022 Results
GL
10/27MDxHealth Reports Q3-2022 Results
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds

2021 Consolidated Figures: English

03/02/2022 | 05:10pm EST

MDxHealth SA and Subsidiaries

2021 Financial Results

as of December 31, 2021

Unaudited consolidated statement of profit and loss

THOUSANDS OF $ (EXCEPT PER SHARE AMOUNTS)

2021

2020

FOR THE YEARS ENDED DECEMBER 31

Services

21,937

18,064

Licenses

250

250

Royalties and other revenues

52

146

Revenues

22,239

18,460

Cost of goods & services sold

(11,675)

(10,416)

Gross profit

10,564

8,044

Research and development expenses

(6,673)

(4,543)

Selling and marketing expenses

(17,744)

(16,752)

General and administrative expenses

(14,149)

(13,990)

Other operating income, net

1,161

118

Operating loss

(26,841)

(27,123)

Financial income

11

4

Financial expenses

(2,172)

(1,543)

Loss before income tax

(29,002)

(28,662)

Income tax

0

0

Loss for the year

(29,002)

(28,662)

Earnings per share attributable to parent (EPS)

Basic and diluted, $

(0.24)

(0.34)

Unaudited consolidated statement of comprehensive income

THOUSANDS OF $

2021

2020

FOR THE YEARS ENDED DECEMBER 31

Loss for the year

(29,002)

(28,662)

Other comprehensive income

Items that will be reclassified to profit or loss:

Exchange differences arising from translation of foreign operations

264

(383)

Total comprehensive loss for the year (net of tax)

(28,738)

(29,045)

MDxHealth SA and Subsidiaries

2021 Financial Results

as of December 31, 2021

Unaudited consolidated statement of financial position

THOUSANDS OF $

2021

2020

FOR THE YEARS ENDED DECEMBER 31

ASSETS

Non-current assets

Intangible assets

3,448

5,058

Property, plant and equipment

1,671

973

Right-of-use assets

3,347

2,734

Total non-current assets

8,466

8,765

Current assets

Inventories

1,911

2,324

Trade receivables

4,582

3,771

Prepaid expenses and other current assets

1,615

1,043

Cash and cash equivalents

58,498

15,953

Total current assets

66,606

23,091

TOTAL ASSETS

75,072

31,856

EQUITY

Share capital

128,454

76,716

Issuance premium

153,177

136,349

Retained earnings

(244,302)

(215,300)

Share-based compensation

10,607

9,385

Translation reserve

(1,037)

(1,301)

Total equity

46,899

5,849

LIABILITIES

Non-current liabilities

Loans and borrowings

7,651

10,279

Lease liabilities

2,624

2,017

Other non-current financial liabilities

1,466

690

Total non-current liabilities

11,741

12,986

Current liabilities

Loans and borrowings

4,441

2,818

Lease liabilities

840

757

Trade payables

7,455

5,320

Other current liabilities

2,735

3,217

Other current financial liabilities

961

909

Total current liabilities

16,432

13,021

Total liabilities

28,173

26,007

TOTAL EQUITY AND LIABILITIES

75,072

31,856

MDxHealth SA and Subsidiaries

2021 Financial Results

as of December 31, 2021

Unaudited consolidated statement of cash flow

THOUSANDS OF $

FOR THE YEARS ENDED DECEMBER 31

2021

2020

CASH FLOWS FROM OPERATING ACTIVITIES

Operating loss

(26,841)

(27,123)

Depreciation and amortization

3,036

3,332

Impairment

0

273

Share-based compensation

1,222

1,295

Other non-cash transactions

(325)

26

Cash used in operations before working capital changes

(22,908)

(22,197)

Decrease / (increase) in inventories

413

(1,132)

(Increase) / decrease in receivables

(1,383)

2,851

Increase in payables

1,653

234

Net cash outflow from OPERATING ACTIVITIES

(22,225)

(20,244)

CASH FLOWS FROM INVESTING ACTIVITIES

Purchase of property, plant and equipment

(1,219)

(537)

Interests received

11

0

Net cash outflow from investing activities

(1,208)

(537)

CASH FLOWS FROM FINANCING ACTIVITIES

Proceeds from issuance of shares (net of transaction costs)

68,566

13,875

Proceeds from the issuance of long-term debt

0

2,316

Payment of lease liability

(1,057)

(831)

Payment of interest

(1,011)

(1,070)

Net cash inflow from financing activities

66,498

14,290

Net increase / (decrease) in cash and cash equivalents

43,065

(6,491)

Cash and cash equivalents at beginning of the financial year

15,953

22,050

Effect on exchange rate changes

(520)

394

Cash and cash equivalents at end of the financial year

58,498

15,953

MDxHealth SA and Subsidiaries

2021 Financial Results

as of December 31, 2021

Unaudited consolidated statement of changes in equity

ATTRIBUTABLE TO OWNERS OF MDXHEALTH SA

THOUSANDS OF $

SHARE

SHARE-

TRANS-

TOTAL

CAPITAL

RETAINED

BASED

EQUITY

LATION

& ISSUANCE

EARNINGS

COMPEN-

RESERVE

PREMIUM

SATION

Balance at January 1, 2020

199,190

(186,638)

8,090

(918)

19,724

Loss for the year

(28,662)

(28,662)

Other comprehensive income

(383)

(383)

Total comprehensive income for the year

(28,662)

(383)

(29,045)

Transactions with owners in their

capacity as owners:

Issuance of shares

14,186

14,186

Deduction of transaction costs

(311)

(311)

Share-based compensation costs

1,295

1,295

Balance at December 31, 2020

213,065

(215,300)

9,385

(1,301)

5,849

Balance at January 1, 2021

213,065

(215,300)

9,385

(1,301)

5,849

Loss for the year

(29,002)

(29,002)

Other comprehensive income

264

264

Total comprehensive income for the year

(29,002)

264

(28,738)

Transactions with owners in their

capacity as owners:

Issuance of shares

75,339

75,339

Deduction of transaction costs

(6,773)

(6,773)

Share-based compensation costs

1,222

1,222

Balance at December 31, 2021

281,631

(244,302)

10,607

(1,037)

46,899

Disclaimer

MDxHealth SA published this content on 28 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 March 2022 22:08:04 UTC.


ę Publicnow 2022
All news about MDXHEALTH SA
11/04European ADRs Move Higher in Friday Trading
MT
10/27MDxHealth Reports Q3-2022 Results
GL
10/27MDxHealth Reports Q3-2022 Results
AQ
10/27MDxHealth SA Reaffirms Revenue Guidance for the Year 2022
CI
10/27MDxHealth SA Reports Earnings Results for the Third Quarter and Nine Months Ended Septe..
CI
08/29Oppenheimer Adjusts MDxHealth Price Target to $21 From $18, Maintains Outperform Rating
MT
08/26BTIG Adjusts Price Target on MDxHealth to $15 From $13, Reiterates Buy Rating
MT
08/26MDXHEALTH SA : Half-year report
CO
08/25MDxHealth SA Reports Earnings Results for the Half Year Ended June 30, 2022
CI
08/25MDxHealth Reports Half Year 2022 Results
GL
More news
Analyst Recommendations on MDXHEALTH SA
More recommendations
Financials
Sales 2022 40,9 M 42,5 M 42,5 M
Net income 2022 -33,9 M -35,3 M -35,3 M
Net Debt 2022 - - -
P/E ratio 2022 -
Yield 2022 -
Capitalization 112 M 117 M 117 M
Capi. / Sales 2022 2,74x
Capi. / Sales 2023 1,65x
Nbr of Employees 191
Free-Float 84,3%
Chart MDXHEALTH SA
Duration : Period :
MDxHealth SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MDXHEALTH SA
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Mean consensus -
Number of Analysts 0
Last Close Price 0,69
Average target price
Spread / Average Target -
Managers and Directors
Michael K. McGarrity Chief Executive Officer & Executive Director
Ron Kalfus Chief Financial Officer
Koen Hoffman Chairman
Miriam Reyes Executive Vice President-Operations
Joseph Sollee Chief Compliance Officer, EVP & General Counsel
Sector and Competitors
1st jan.Capi. (M$)
MDXHEALTH SA-22.00%117
MODERNA, INC.-30.55%67 769
IQVIA HOLDINGS INC.-22.03%40 859
LONZA GROUP AG-33.93%39 445
ALNYLAM PHARMACEUTICALS, INC.25.44%26 171
SEAGEN INC.-20.16%22 918